<DOC>
	<DOCNO>NCT00238901</DOCNO>
	<brief_summary>The natural history HCV infection liver transplant recipient may accelerate compare patient normal immune system . The objective trial ass efficacy safety basiliximab , combination cyclosporin MMF success rate liver transplant HCV related cirrhosis , comparison standard steroid treatment .</brief_summary>
	<brief_title>Efficacy Safety Basiliximab Hepatitis C Virus Positive Patients Undergoing Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Patients undergo first cadaver liver transplant Patients receive AB0 identical compatible graft HCV+ patient ( serology test within last 12 month ) Exclusion Criteria Antiretroviral prophylactic treatment posttransplant Serological marker positive Hepatitis B surface Antigen Human Immunodeficiency Virus Recipients split liver transplant Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Liver transplant , HCV+ , steroid free</keyword>
</DOC>